Therascreen EGFR RGQ PCR Kit

Somatic Gene Mutation Detection System

FDA Premarket Approval P120022 S016

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for extending the labeling claim of the therascreen® egfr rgq pcr kit to include detection of egfr mutations l861q, g719x and s768i, to aid in identifying patients with nsclc for whom safety and efficacy of gilotrif® (afatininb) has been established.

DeviceTherascreen EGFR RGQ PCR Kit
Classification NameSomatic Gene Mutation Detection System
Generic NameSomatic Gene Mutation Detection System
ApplicantQIAGEN MANCHESTER LTD
Date Received2017-07-28
Decision Date2018-01-12
PMAP120022
SupplementS016
Product CodeOWD
Advisory CommitteePathology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address QIAGEN MANCHESTER LTD skelton House lloyd Street North manchester M15 6

Supplemental Filings

Supplement NumberDateSupplement Type
P120022Original Filing
S022 2020-10-23 Real-time Process
S021 2020-03-04 30-day Notice
S020 2019-08-28 Special (immediate Track)
S019 2018-03-08 30-day Notice
S018 2018-02-16 Normal 180 Day Track
S017 2018-01-26 30-day Notice
S016 2017-07-28 Normal 180 Day Track
S015 2017-06-29 30-day Notice
S014 2016-12-28 Normal 180 Day Track
S013 2016-08-10 30-day Notice
S012 2015-09-28 Normal 180 Day Track No User Fee
S011
S010 2015-02-18 Normal 180 Day Track
S009 2015-01-26 Real-time Process
S008 2015-01-26 Real-time Process
S007 2015-01-21 30-day Notice
S006 2015-01-21 30-day Notice
S005 2014-12-22 30-day Notice
S004 2014-12-15 30-day Notice
S003
S002 2014-11-19 30-day Notice
S001 2014-09-18 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.